(Q34033249)

30 July 2017

1 reference

title

Viral hepatitis in the liver transplant recipient (English)

1 reference

30 July 2017

1 reference

Rosen HR

1

1 reference

30 July 2017

Martin P

series ordinal

2

1 reference

30 July 2017

language of work or name

1 reference

1 September 2000

1 reference

Infectious Disease Clinics of North America

30 July 2017

published in

1 reference

30 July 2017

volume

14

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

761-784

1 reference

The epidemiology of acute and chronic hepatitis C.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Hepatitis C associated glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Long-term outcome of hepatitis C virus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Interactions between alcohol and hepatitis viruses in the liver.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Predictors of patient and graft survival following liver transplantation for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Quantitation of hepatitis C virus RNA in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Severe clinical course of de novo hepatitis B infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Retransplantation in hepatitis B--a multicenter experience

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Clinical and histologic patterns of early graft failure due to recurrnet hepatitis C in four patients after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Infectivity of hepatic allografts with antibodies to hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Hepatitis C viral infection in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

A longitudinal analysis of hepatitis C virus replication following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Long-term outcome of hepatitis C infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Do viral genotypes and HLA matching influence the outcome of recurrent hepatitis C virus infection after liver transplantation?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Clinical outcome of hepatitis C as a function of mode of transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Liver transplantation in Asian patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Hepatitis B and C coinfections and persistent hepatitis B infections: clinical outcome and liver pathology after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Sanctuary of hepatitis B virus in bone-marrow cells of patients undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Retransplantation of patients with severe posttransplant hepatitis B in the first allograft

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Liver transplantation for chronic hepatitis B in Asians

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Infrequent vertical transmission of hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Patterns of hepatitis delta virus reinfection and disease in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Retransplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Molecular epidemiology of hepatitis C infection in U.S. veteran liver transplant recipients: evidence for decreasing relative prevalence of genotype 1B.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Hepatitis C virus: current understanding and prospects for future therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Donor polymorphism of tumor necrosis factor gene: relationship with variable severity of hepatitis C recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Hepatitis C infection in patients undergoing liver retransplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

OKT3 and hepatitis C: defining the risks

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Graft loss following liver transplantation in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Acquisition of hepatitis C by a conjunctival splash

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Primer on hepatitis C for hospital epidemiologists.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Liver transplantation in European patients with the hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Histological and clinical outcome after liver transplantation for hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Interferon alfa for recurrent hepatitis B infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

The influence of hepatitis C virus genotypes on the outcome of liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

FK506 in liver transplantation for chronic hepatitis B: In vitro studies on lymphocyte activation and virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

The long-term pathological evolution of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970130-6

7 January 2021

10.1016/S0891-5520(05)70130-6

Identifiers

DOI

1 reference

30 July 2017

1 reference